NCT04846166

I-Smads in Periodontitis

Role of Inhibitor SMADs in Stage 3 Grade B Periodontitis Before and After Periodontal Treatment

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 40 (actual)
• Sponsor: Bulent Ecevit University · Academic / Other
• Sex: All
• Age: 25 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Recently, it has been stated that Smads play an active role in all conditions where transforming growth factor-beta (TGF-β) is involved, including periodontal inflammation. This study aimed to examine the levels of TGF-β and inhibitor Smads in saliva and gingival crevicular fluid (GCF) in patients with Stage 3 Grade B periodontitis before and after non-surgical periodontal treatment. Twenty (20) stage 3 grade B periodontitis and 20 periodontally healthy individuals were included in the study. Clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and GCF and saliva samples were obtained at baseline and one month after treatment. TGF-β, Smad6, and Smad7 were determined by ELISA.

Conditions

• Periodontitis
• Treatment Adherence

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Periodontally healthy group	probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
DIAGNOSTIC_TEST	Periodontitis	: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth

Timeline

• Start date: 2019-08-01
• Primary completion: 2020-03-01
• Completion: 2020-03-01
• First posted: 2021-04-15
• Last updated: 2021-04-19

Locations

1 site across 1 country: Turkey (Türkiye)